Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Duboc, D.
Right arrow Articles by Bécane, H.-M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Duboc, D.
Right arrow Articles by Bécane, H.-M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Perindopril preserves left ventricular function in X-linked Duchenne muscular dystrophy

Denis Duboc1,*, Christophe Meune1, Bertrand Pierre1, Karim Wahbi1,2, Bruno Eymard2, Annick Toutain3, Carole Berard4, Guy Vaksmann5 and Henri-Marc Bécane2

1 Department of Cardiology, Cochin Hospital, APHP, Paris V René Descartes University, 27 rue du Fg St-Jacques, Paris 75014, France
2 Myology Institute, Pitié-Salpétrière Hospital, Paris, France
3 Department of Genetics, Bretonneau University Hospital, Tours, France
4 Department of Pediatric Rehabilitation, Lyon-Sud Hospital, Lyon, France
5 Department of Pediatrics, Cardiology Hospital, Lille, France

* Corresponding author. Tel: +33 1 58 41 16 56; fax: +33 1 58 41 16 05. E-mail address: denis.duboc{at}cch.aphp.fr

Duchenne muscular dystrophy (DMD), an X-linked disorder due to a lack of dystrophin, is associated with muscle weakness and myocardial dysfunction. DMD children between the ages of 9.5 and 13 years with normal left ventricular ejection fraction were included in this prospective study. They were randomly assigned for 3 years to perindopril 2–4 mg (group 1) or placebo (group 2) in a double-blind protocol, followed by open-label treatment with perindopril for all patients. Left ventricular function was compared between the two groups at 5 years. A total of 28 patients were assigned to group 1 and 29 patients were assigned to group 2. Baseline characteristics were similar in both groups. At the end of the 5-year follow-up period, eight patients had an ejection fraction under 45% in the placebo group vs. one patient in the perindopril group (P < 0.02). All patients were alive in the perindopril group and three had died in the placebo group (P = 0.07). Early initiation of treatment with perindopril is associated with a preservation of left ventricular function in DMD children and with a trend towards a lower mortality.

Key Words: Duchenne muscular dystrophy • Cardiac dysfunction • Cardiomyopathy • Perindopril • Angiotensin-converting enzyme inhibition


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
M. Tendera
Introduction
Eur. Heart J. Suppl., September 1, 2007; 9(suppl_E): E1 - E1.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.